Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis

Expert Review of Anti-Infective Therapy

Volumn 8, Issue 4, 2010, Pages 419-433

  Goto, Hiro ^a   Lindoso, José Angelo Lauletta ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Amphotericin B; Coinfection; ELISA; HIV; Human; Leishmania; PCR; Pentamidine; Pentavalent antimonials; Serodiagnosis

Indexed keywords

ALLOPURINOL; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIMONY DERIVATIVE; AZITHROMYCIN; BCG VACCINE; DAPSONE; FLUCONAZOLE; IMIDAZOLE; IMIQUIMOD; ITRACONAZOLE; KETOCONAZOLE; MEGLUMINE ANTIMONATE; METHYLBENZETHONIUM CHLORIDE; MILTEFOSINE; PAROMOMYCIN; PENTAMIDINE; PYRROLE DERIVATIVE; RIFAMPICIN; STIBOGLUCONATE SODIUM; TAMOXIFEN;

AMASTIGOTE; ARTHRALGIA; CARDIOTOXICITY; CELL MEMBRANE PERMEABILITY; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DNA DETERMINATION; DRUG EFFICACY; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; HYPOGLYCEMIA; IMMUNOFLUORESCENCE TEST; IMMUNOMODULATION; IMMUNOTHERAPY; KIDNEY FAILURE; KIDNEY INJURY; LABORATORY TEST; LEISHMANIA; LEISHMANIA BRAZILIENSIS; LEISHMANIA MAJOR; LEISHMANIA MEXICANA; LEISHMANIA TROPICA; LEISHMANIASIS; LEISHMANIN SKIN TEST; MIXED INFECTION; MOLECULAR DIAGNOSIS; MYALGIA; MYCOBACTERIOSIS; NONHUMAN; PARASITE IDENTIFICATION; REAL TIME POLYMERASE CHAIN REACTION; RECOMMENDED DRUG DOSE; REVIEW; SERODIAGNOSIS; SEROLOGY; SKIN LEISHMANIASIS; SKIN TEST; SPOROTRICHOSIS; VENOUS STASIS; VISCERAL LEISHMANIASIS;

EID: 77950849328     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.10.19     Document Type: Review

References (123)

1. Desjeux P. Leishmaniasis: current situation and new perspectives. Comp. Immunol. Microbiol. Infect. Dis. 27, 305-318 (2004).
2. Schwartz E, Hatz C, Blum J. New world cutaneous leishmaniasis in travelers. Lancet Infect. Dis. 6, 342-349 (2006).
3. Murray HW, Berman JD, Davies CR, Saravia NG. Advances in leishmaniasis. Lancet 366, 1561-1577 (2005).
4. Shaw JJ, Lainson R. Ecology and epidemiology: New World. In: The Leishmaniases in Biology and Medicine (Volume I). Peters W, Killick-Kendrick R (Eds). Academic Press, London, UK, 291-363 (1987).
5. Ashford RW, Bettini S. Ecology and epidemiology: Old World. In: The Leishmaniases in Biology and Medicine (Volume I). Peters W, Killick-Kendrick R (Eds). Academic Press, London, UK, 365-424 (1987).
6. Lederman ER, Weld LH, Elyazar IR et al. Dermatologic conditions of the ill returned traveler: an analysis from the GeoSentinel Surveillance Network. Int. J. Infect. Dis. 12, 593-602 (2008).
7. Scarisbrick JJ, Chiodini PL, Watson J et al. Clinical features and diagnosis of 42 travellers with cutaneous leishmaniasis. Travel Med. Infect. Dis. 4, 14-21 (2006).
8. El Hajj L, Thellier M, Carriere J, Bricaire F, Danis M, Caumes E. Localized cutaneous leishmaniasis imported into Paris: a review of 39 cases. Int. J. Dermatol. 43, 120-125 (2004).
9. Walton BC. American cutaneous and mucocutaneous leishmaniasis. In: The Leishmaniases in Biology and Medicine (Volume II). Peters W, Killick-Kendrick R (Eds). Academic Press, London, UK, 637-664 (1987).
10. Machado P, Araujo C, Da Silva AT et al. Failure of early treatment of cutaneous leishmaniasis in preventing the development of an ulcer. Clin. Infect. Dis. 34, E69-E73 (2002).
11. Akilov OE, Khachemoune A, Hasan T. Clinical manifestations and classification of Old World cutaneous leishmaniasis. Int. J. Dermatol. 46, 132-142 (2007).
12. Kharfi M, Fazaa B, Chaker E, Kamoun MR. [Mucosal localization of leishmaniasis in Tunisia: 5 cases]. Ann. Dermatol. Venereol. 130, 27-30 (2003).
13. Zijlstra EE, Musa AM, Khalil EA, el-Hassan IM, el-Hassan AM. Post-kala-azar dermal leishmaniasis. Lancet Infect. Dis. 3, 87-98 (2003).
14. Oliveira-Neto MP, Mattos M, Souza CS, Fernandes O, Pirmez C. Leishmaniasis recidiva cutis in New World cutaneous leishmaniasis. Int. J. Dermatol. 37, 846-849 (1998).
15. Bittencourt AL, Costa JM, Carvalho EM, Barral A. Leishmaniasis recidiva cutis in American cutaneous leishmaniasis. Int. J. Dermatol. 32, 802-805 (1993).
16. Calvopina M, Uezato H, Gomez EA, Korenaga M, Nonaka S, Hashiguchi Y. Leishmaniasis recidiva cutis due to Leishmania (Viannia) panamensis in subtropical Ecuador: isoenzymatic characterization. Int. J. Dermatol. 45, 116-120 (2006).
17. Reithinger R, Dujardin JC, Louzir H, Pirmez C, Alexander B, Brooker S. Cutaneous leishmaniasis. Lancet Infect. Dis. 7, 581-596 (2007).
18. Turetz ML, Machado PR, Ko AI et al. Disseminated leishmaniasis: a new and emerging form of leishmaniasis observed in northeastern Brazil. J. Infect. Dis. 186, 1829-1834 (2002).
19. Costa JM, Marsden PD, Llanos- Cuentas EA et al. Disseminated cutaneous leishmaniasis in a field clinic in Bahia, Brazil: a report of eight cases. J. Trop. Med. Hyg. 89, 319-323 (1986).
20. Barral A, Costa JM, Bittencourt AL, Barral-Netto M, Carvalho EM. Polar and subpolar diffuse cutaneous leishmaniasis in Brazil: clinical and immunopathologic aspects. Int. J. Dermatol. 34(7), 474-479 (1995).
21. De Castro EA, Luz E, Telles FQ et al. Eco-epidemiological survey of Leishmania (Viannia) braziliensis American cutaneous and mucocutaneous leishmaniasis in Ribeira Valley River, Parana State, Brazil. Acta Trop. 93, 141-149 (2005).
22. Gontijo CM, da Silva ES, De Fuccio MB et al. Epidemiological studies of an outbreak of cutaneous leishmaniasis in the Rio Jequitinhonha Valley, Minas Gerais, Brazil. Acta Trop. 81, 143-150 (2002).
23. Jones TC, Johnson WD Jr, Barretto AC et al. Epidemiology of American cutaneous leishmaniasis due to Leishmania braziliensis braziliensis. J. Infect. Dis. 156, 73-83 (1987).
24. Davies CR, Reithinger R, Campbell- Lendrum D, Feliciangeli D, Borges R, Rodriguez N. The epidemiology and control of leishmaniasis in Andean countries. Cad. Saude Publica 16, 925-950 (2000).
25. Garcia AL, Parrado R, Rojas E, Delgado R, Dujardin JC, Reithinger R. Leishmaniases in Bolivia: comprehensive review and current status. Am. J. Trop. Med. Hyg. 80, 704-711 (2009).
26. Hashiguchi Y, Gomez Landires EA. A review of leishmaniasis in Ecuador. Bull. Pan. Am. Health Organ. 25, 64-76 (1991).
27. Puig L, Pradinaud R. Leishmania and HIV co-infection: dermatological manifestations. Ann. Trop. Med. Parasitol. 97(Suppl. 1), 107-114 (2003).
28. Lindoso JA, Barbosa RN, Posada- Vergara MP et al. Unusual manifestations of tegumentary leishmaniasis in AIDS patients from the New World. Br. J. Dermatol. 160, 311-318 (2009).
29. Posada-Vergara MP, Lindoso JA, Tolezano JE, Pereira-Chioccola VL, Silva MV, Goto H. Tegumentary leishmaniasis as a manifestation of immune reconstitution inflammatory syndrome in 2 patients with AIDS. J. Infect. Dis. 192, 1819-1822 (2005).
30. David CV, Craft N. Cutaneous and mucocutaneous leishmaniasis. Dermatol. Ther. 22, 491-502 (2009).
31. Vega-Lopez F. Diagnosis of cutaneous leishmaniasis. Curr. Opin. Infect. Dis. 16, 97-101 (2003).
32. Al-Hucheimi SN, Sultan BA, Al- Dhalimi MA. A comparative study of the diagnosis of Old World cutaneous leishmaniasis in Iraq by polymerase chain reaction and microbiologic and histopathologic methods. Int. J. Dermatol. 48, 404-408 (2009).
33. Sotto MN, Yamashiro-Kanashiro EH, da Matta VL, De Brito T. Cutaneous leishmaniasis of the New World: diagnostic immunopathology and antigen pathways in skin and mucosa. Acta Trop. 46, 121-130 (1989).
34. Schubach A, Cuzzi-Maya T, Oliveira AV et al. Leishmanial antigens in the diagnosis of active lesions and ancient scars of American tegumentary leishmaniasis patients. Mem. Inst. Oswaldo Cruz 96, 987-996 (2001).
35. Weigle KA, De Davalos M, Heredia P, Molineros R, Saravia NG, D'Alessandro A. Diagnosis of cutaneous and mucocutaneous leishmaniasis in Colombia: a comparison of seven methods. Am. J. Trop. Med. Hyg. 36, 489-496 (1987).
36. Reithinger R, Dujardin JC. Molecular diagnosis of leishmaniasis: current status and future applications. J. Clin. Microbiol. 45, 21-25 (2007).
37. Grimaldi G, McMahon-Pratt D. Monoclonal antibodies for the identification of New World Leishmania species. Mem. Inst. Oswaldo Cruz 91, 37-42 (1996).
38. Cupolillo E, Grimaldi G Jr, Momen H. Discrimination of Leishmania isolates using a limited set of enzymatic loci. Ann. Trop. Med. Parasitol. 89, 17-23 (1995).
39. Van Eys GJ, Schoone GJ, Kroon NC, Ebeling SB. Sequence analysis of small subunit ribosomal RNA genes and its use for detection and identification of Leishmania parasites. Mol. Biochem. Parasitol. 51, 133-142 (1992).
40. Russell R, Iribar MP, Lambson B et al. Intra and inter-specific microsatellite variation in the Leishmania subgenus Viannia. Mol. Biochem. Parasitol. 103, 71-77 (1999).
41. Piarroux R, Azaiez R, Lossi AM et al. Isolation and characterization of a repetitive DNA sequence from Leishmania infantum: development of a visceral leishmaniasis polymerase chain reaction. Am. J. Trop. Med. Hyg. 49, 364-369 (1993).
42. Luis L, Ramirez A, Aguilar CM, Eresh S, Barker DC, Mendoza-Leon A. The genomic fingerprinting of the coding region of the b-tubulin gene in Leishmania identification. Acta Trop. 69, 193-204 (1998).
43. Victoir K, Banuls AL, Arevalo J et al. The gp63 gene locus, a target for genetic characterization of Leishmania belonging to subgenus Viannia. Parasitology 117(Pt 1), 1-13 (1998).
44. Cupolillo E, Grimaldi Júnior G, Momen H, Beverley SM. Intergenic region typing (IRT): a rapid molecular approach to the characterization and evolution of Leishmania. Mol. Biochem. Parasitol. 73, 145-155 (1995).
45. Eisenberger CL, Jaffe CL. Leishmania: identification of Old World species using a permissively primed intergenic polymorphic-polymerase chain reaction. Exp. Parasitol. 91, 70-77 (1999).
46. De Bruijn MH, Barker DC. Diagnosis of New World leishmaniasis: specific detection of species of the Leishmania braziliensis complex by amplification of kinetoplast DNA. Acta Trop. 52, 45-58 (1992).
47. Nasereddin A, Bensoussan-Hermano E, Schonian G, Baneth G, Jaffe CL. Molecular diagnosis of old world cutaneous leishmaniasis and species identification by use of a reverse line blot hybridization assay. J. Clin. Microbiol. 46, 2848-2855 (2008).
48. Oliveira JG, Novais FO, De Oliveira CI et al. Polymerase chain reaction (PCR) is highly sensitive for diagnosis of mucosal leishmaniasis. Acta Trop. 94, 55-59 (2005).
49. Castilho TM, Shaw JJ, Floeter-Winter LM. New PCR assay using glucose-6-phosphate dehydrogenase for identification of Leishmania species. J. Clin. Microbiol. 41, 540-546 (2003).
50. Zhang WW, Miranda-Verastegui C, Arevalo J et al. Development of a genetic assay to distinguish between Leishmania viannia species on the basis of isoenzyme differences. Clin. Infect. Dis. 42, 801-809 (2006).
51. Garcia L, Kindt A, Bermudez H et al. Culture-independent species typing of neotropical Leishmania for clinical validation of a PCR-based assay targeting heat shock protein 70 genes. J. Clin. Microbiol. 42, 2294-2297 (2004).
52. Marfurt J, Niederwieser I, Makia ND, Beck HP, Felger I. Diagnostic genotyping of Old and New World Leishmania species by PCR-RFLP. Diagn. Microbiol. Infect. Dis. 46, 115-124 (2003).
53. De Monbrison F, Mihoubi I, Picot S. Real-time PCR assay for the identification of cutaneous Leishmania parasite species in Constantine region of Algeria. Acta Trop. 102, 79-83 (2007).
54. Antinori S, Calattini S, Piolini R et al. Is real-time polymerase chain reaction (PCR) more useful than a conventional PCR for the clinical management of leishmaniasis? Am. J. Trop. Med. Hyg. 81, 46-51 (2009).
55. Castilho TM, Camargo LM, McMahon- Pratt D, Shaw JJ, Floeter-Winter LM. A real-time polymerase chain reaction assay for the identification and quantification of American Leishmania species on the basis of glucose-6-phosphate dehydrogenase. Am. J. Trop. Med. Hyg. 78, 122-132 (2008).
56. Sassi A, Louzir H, Ben Salah A, Mokni M, Ben Osman A, Dellagi K. Leishmanin skin test lymphoproliferative responses and cytokine production after symptomatic or asymptomatic Leishmania major infection in Tunisia. Clin. Exp. Immunol. 116, 127-132 (1999).
57. Reed SG. Diagnosis of leishmaniasis. Clin. Dermatol. 24, 471-478 (1996).
58. Shaw JJ, Lainson R. Leishmaniasis in Brazil: X. Some observations of intradermal reactions to different trypanosomatid antigens of patients suffering from cutaneous and mucocutaneous leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 69, 323-335 (1975).
59. Luz ZM, Silva AR, Silva Fde O, Caligiorne RB, Oliveira E, Rabello A. Lesion aspirate culture for the diagnosis and isolation of Leishmania spp. from patients with cutaneous leishmaniasis. Mem. Inst. Oswaldo Cruz 104, 62-66 (2009).
60. Reis Lde C, Brito ME, Almeida EL et al. Clinical, epidemiological and laboratory aspects of patients with American cutaneous leishmaniasis in the State of Pernambuco. Rev. Soc. Bras. Med. Trop. 41, 439-443 (2008).
61. Bryceson AD. Diffuse cutaneous leishmaniasis in Ethiopia. 3. Immunological studies. IV. Pathogenesis of diffuse cutaneous leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 64, 380-393 (1970).
62. Kar K. Serodiagnosis of leishmaniasis. Crit. Rev. Microbiol. 21, 123-152 (1995).
63. Edrissian GH, Darabian P. A comparison of enzyme-linked immunosorbent assay and indirect fluorescent antibody test in the sero-diagnosis of cutaneous and visceral leishmaniasis in Iran. Trans. R. Soc. Trop. Med. Hyg. 73, 289-292 (1979).
64. el Safi SH, Evans DA. A comparison of the direct agglutination test and enzyme-linked immunosorbent assay in the sero-diagnosis of leishmaniasis in the Sudan. Trans. R. Soc. Trop. Med. Hyg. 83, 334-337 (1989).
65. Zeyrek FY, Korkmaz M, Ozbel Y. Serodiagnosis of anthroponotic cutaneous leishmaniasis (ACL) caused by Leishmania tropica in Sanliurfa Province, Turkey, where ACL is highly endemic. Clin. Vaccine Immunol. 14, 1409-1415 (2007).
66. Guimaraes MC, Celeste BJ, Franco EL. Diagnostic performance indices for immunofluorescent tests and enzyme immunoassays of leishmaniasis sera from northern and north-eastern Brazil. Bull. World Health Organ. 68, 39-43 (1990).
67. Guimaraes MC, Celeste BJ, Franco EL, Cuce LC, Belda W Jr. Evaluation of serological diagnostic indices for mucocutaneous leishmaniasis: immunofluorescence tests and enzyme-linked immunoassays for IgG, IgM and IgA antibodies. Bull. World Health Organ. 67, 643-648 (1989).
68. Barroso-Freitas AP, Passos SR, Mouta-Confort E et al. Accuracy of an ELISA and indirect immunofluorescence for the laboratory diagnosis of American tegumentary leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 103, 383-389 (2009).
69. Romero GA, De la Gloria Orge Orge M, De Farias Guerra MV, Paes MG, De Oliveira Macedo V, De Carvalho EM. Antibody response in patients with cutaneous leishmaniasis infected by Leishmania (Viannia) braziliensis or Leishmania (Viannia) guyanensis in Brazil. Acta Trop. 93, 49-56 (2005).
70. Hailu A. The use of direct agglutination test (DAT) in serological diagnosis of Ethiopian cutaneous leishmaniasis. Diagn. Microbiol. Infect. Dis. 42, 251-256 (2002).
71. Rey-Ladino JA, Joshi PB, Singh B, Gupta R, Reiner NE. Leishmania major: molecular cloning, sequencing, and expression of the heat shock protein 60 gene reveals unique carboxy terminal peptide sequences. Exp. Parasitol. 85, 249-263 (1997).
72. Amorim AG, Carrington M, Miles MA, Barker DC, De Almeida ML. Identification of the C-terminal region of 70 kDa heat shock protein from Leishmania (Viannia) braziliensis as a target for the humoral immune response. Cell Stress Chaperones 1, 177-187 (1996).
73. Celeste BJ, Angel SO, Castro LG, Gidlund M, Goto H. Leishmania infantum heat shock protein 83 for the serodiagnosis of tegumentary leishmaniasis. Braz. J. Med. Biol. Res. 37, 1591-1593 (2004).
74. Alvar J, Aparicio P, Aseffa A et al. The relationship between leishmaniasis and AIDS: the second 10 years. Clin. Microbiol. Rev. 21, 334-359 (2008).
75. Boelaert M, El-Safi S, Hailu A et al. Diagnostic tests for kala-azar: a multi-centre study of the freeze-dried DAT, rK39 strip test and KAtex in East Africa and the Indian subcontinent. Trans. R. Soc. Trop. Med. Hyg. 102, 32-40 (2008).
76. Mahajan VK, Sharma NL. Therapeutic options for cutaneous leishmaniasis. J. Dermatolog. Treat. 18, 97-104 (2007).
77. Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin. Microbiol. Rev. 19, 111-126 (2006).
78. Bermudez H, Rojas E, Garcia L et al. Generic sodium stibogluconate is as safe and effective as branded meglumine antimoniate, for the treatment of tegumentary leishmaniasis in Isiboro Secure Park, Bolivia. Ann. Trop. Med. Parasitol. 100, 591-600 (2006).
79. Oliveira-Neto MP, Schubach A, Mattos M, Goncalves-Costa SC, Pirmez C. A low-dose antimony treatment in 159 patients with American cutaneous leishmaniasis: extensive follow-up studies (up to 10 years). Am. J. Trop. Med. Hyg. 57, 651-655 (1997).
80. Palacios R, Osorio LE, Grajalew LF, Ochoa MT. Treatment failure in children in a randomized clinical trial with 10 and 20 days of meglumine antimonate for cutaneous leishmaniasis due to Leishmania viannia species. Am. J. Trop. Med. Hyg. 64, 187-193 (2001).
81. Franke ED, Wignall FS, Cruz ME et al. Efficacy and toxicity of sodium stibogluconate for mucosal leishmaniasis. Ann. Intern. Med. 113, 934-940 (1990).
82. Romero GA, Lessa HA, Orge MG, Macedo VO, Marsden PD. [Treatment of mucosal leishmaniasis with aminosidine sulfate: results of two year follow-up]. Rev. Soc. Bras. Med. Trop. 31, 511-516 (1998).
83. Amato VS, Tuon FF, Imamura R, Abegao De Camargo R, Duarte MI, Neto VA. Mucosal leishmaniasis: description of case management approaches and analysis of risk factors for treatment failure in a cohort of 140 patients in Brazil. J. Eur. Acad. Dermatol. Venereol. 23, 1026-1034 (2009).
84. Ellis M, Bernsen R, Ali-Zadeh H et al. A safety and feasibility study comparing intermittent high dose with daily standard dose liposomal amphotericin B for persistent neutropenic fever amphotericin B: spectrum and resistance. J. Med. Microbiol. 49(Suppl. 1), 7-10 (2009).
85. Tuon FF, Amato VS, Graf ME et al. Treatment of New World cutaneous leishmaniasis - a systematic review with a meta-analysis. Int. J. Dermatol. 47, 109-124 (2008).
86. Soto J, Toledo J, Gutierrez P et al. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin. Infect. Dis. 33, E57-E61 (2001).
87. Soto J, Arana BA, Toledo J et al. Miltefosine for new world cutaneous leishmaniasis. Clin. Infect. Dis. 38, 1266-1272 (2004).
88. Khatami A, Firooz A, Gorouhi F, Dowlati Y. Treatment of acute Old World cutaneous leishmaniasis: a systematic review of the randomized controlled trials. J. Am. Acad. Dermatol. 57, 335 e331-e329 (2007).
89. Llanos-Cuentas A, Echevarria J, Seas C et al. Parenteral aminosidine is not effective for Peruvian mucocutaneous leishmaniasis. Am. J. Trop. Med. Hyg. 76, 1128-1131 (2007).
90. Kim DH, Chung HJ, Bleys J, Ghohestani RF. Is paromomycin an effective and safe treatment against cutaneous leishmaniasis? A meta-analysis of 14 randomized controlled trials. PLoS Negl. Trop. Dis. 3, e381 (2009).
91. Prata A, Silva-Vergara ML, Costa L et al. Efficacy of azithromycin in the treatment of cutaneous leishmaniasis. Rev. Soc. Bras. Med. Trop. 36, 65-69 (2003).
92. Layegh P, Yazdanpanah MJ, Vosugh EM, Pezeshkpoor F, Shakeri MT, Moghiman T. Efficacy of azithromycin versus systemic meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis. Am. J. Trop. Med. Hyg. 77, 99-101 (2007).
93. Velez I, Agudelo S, Hendrickx E et al. Inefficacy of allopurinol as monotherapy for Colombian cutaneous leishmaniasis. A randomized, controlled trial. Ann. Intern. Med. 126, 232-236 (1997).
94. Llanos-Cuentas A, Echevarria J, Cruz M et al. Efficacy of sodium stibogluconate alone and in combination with allopurinol for treatment of mucocutaneous leishmaniasis. Clin. Infect. Dis. 25, 677-684 (1997).
95. Dogra J. A double-blind study on the efficacy of oral dapsone in cutaneous leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 85, 212-213 (1991).
96. Osorio LE, Palacios R, Chica ME, Ochoa MT. Treatment of cutaneous leishmaniasis in Colombia with dapsone. Lancet 351, 498-499 (1998).
97. Joshi RK, Nambiar PM. Dermal leishmaniasis and rifampicin. Int. J. Dermatol. 28, 612-614 (1989).
98. Kochar DK, Saini G, Kochar SK et al. A double blind, randomised placebo controlled trial of rifampicin with omeprazole in the treatment of human cutaneous leishmaniasis. J. Vector Borne Dis. 43, 161-167 (2006).
99. Bygbjerg IC, Knudsen L, Kieffer M. Failure of rifampin therapy to cure cutaneous leishmaniais. Arch. Dermatol. 116, 988 (1980).
100. Do Valle TZ, Oliveira Neto MP, Schubach A, Lagrange PH, Da Costa SC. New World tegumentar leishmaniasis: chemotherapeutic activity of rifampicin in humans and experimental murine model. Pathol. Biol. (Paris) 43, 618-621 (1995).
101. al-Gindan Y, Kubba R, el-Hassan AM, Omer AH, Kutty MK, Saeed MB. Dissemination in cutaneous leishmaniasis. 3. Lymph node involvement. Int. J. Dermatol. 28, 248-254 (1989).
102. Van Der Snoek EM, Robinson DJ, Van Hellemond JJ, Neumann HA. A review of photodynamic therapy in cutaneous leishmaniasis. J. Eur. Acad. Dermatol. Venereol. 22, 918-922 (2008).
103. Kaur S, Shivange AV, Roy N. Structural analysis of trypanosomal sirtuin: an insight for selective drug design. Mol. Divers. 14(1), 169-178 (2010).
104. Das BB, Sen N, Dasgupta SB, Ganguly A, Das R, Majumder HK. Topoisomerase research of kinetoplastid parasite Leishmania, with special reference to development of therapeutics. Indian J. Med. Res. 123, 221-232 (2006).
105. Desai PV, Patny A, Gut J et al. Identification of novel parasitic cysteine protease inhibitors by use of virtual screening. 2. The available chemical directory. J. Med. Chem. 49, 1576-1584 (2006).
106. Arruda DC, D'Alexandri FL, Katzin AM, Uliana SR. Antileishmanial activity of the terpene nerolidol. Antimicrob. Agents Chemother. 49, 1679-1687 (2005).
107. Miguel DC, Yokoyama-Yasunaka JK, Uliana SR. Tamoxifen is effective in the treatment of Leishmania amazonensis infections in mice. PLoS Negl. Trop. Dis. 2, e249 (2008).
108. Miguel DC, Zauli-Nascimento RC, Yokoyama-Yasunaka JK, Katz S, Barbieri CL, Uliana SR. Tamoxifen as a potential antileishmanial agent: efficacy in the treatment of Leishmania braziliensis and Leishmania chagasi infections. J. Antimicrob. Chemother. 63, 365-368 (2009).
109. Kumari S, Kumar A, Samant M, Singh N, Dube A. Discovery of novel vaccine candidates and drug targets against visceral leishmaniasis using proteomics and transcriptomics. Curr. Drug Targets 9, 938-947 (2008).
110. Convit J, Ulrich M, Zerpa O et al. Immunotherapy of american cutaneous leishmaniasis in Venezuela during the period 1990-1999. Trans. R. Soc. Trop. Med. Hyg. 97, 469-472 (2003).
111. Mayrink W, Magalhaes PA, Michalick MS et al. Immunotherapy as a treatment of American cutaneous leishmaniasis: preliminary studies in Brazil. Parassitologia 34, 159-165 (1992).
112. Coler RN, Goto Y, Bogatzki L, Raman V, Reed SG. Leish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD4+ T cells. Infect. Immun. 75, 4648-4654 (2007).
113. Badaro R, Lobo I, Munos A et al. Immunotherapy for drug-refractory mucosal leishmaniasis. J. Infect. Dis. 194, 1151-1159 (2006).
114. Musa AM, Noazin S, Khalil EA, Modabber F. Immunological stimulation for the treatment of leishmaniasis: a modality worthy of serious consideration. Trans. R. Soc. Trop. Med. Hyg. 104(1), 1-2 (2009).
115. Bacellar O, Lessa H, Schriefer A et al. Up-regulation of Th1-type responses in mucosal leishmaniasis patients. Infect. Immun. 70, 6734-6740 (2002).
116. Carvalho LP, Passos S, Bacellar O et al. Differential immune regulation of activated T cells between cutaneous and mucosal leishmaniasis as a model for pathogenesis. Parasite Immunol. 29, 251-258 (2007).
117. Machado PR, Lessa H, Lessa M et al. Oral pentoxifylline combined with pentavalent antimony: a randomized trial for mucosal leishmaniasis. Clin. Infect. Dis. 44, 788-793 (2007).
118. Sadeghian G, Nilforoushzadeh MA. Effect of combination therapy with systemic glucantime and pentoxifylline in the treatment of cutaneous leishmaniasis. Int. J. Dermatol. 45, 819-821 (2006).
119. Arevalo I, Ward B, Miller R et al. Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator. Clin. Infect. Dis. 33, 1847-1851 (2001).
120. Arevalo I, Tulliano G, Quispe A et al. Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous leishmaniasis. Clin. Infect. Dis. 44, 1549-1554 (2007).
121. Miranda-Verastegui C, Tulliano G, Gyorkos TW et al. First-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimony. PLoS Negl. Trop. Dis. 3(7), e491 (2009).
122. Gonzalez U, Pinart M, Reveiz L, Alvar J. Interventions for Old World cutaneous leishmaniasis. Cochrane Database Syst. Rev. CD005067 (2008).
123. Gonzalez U, Pinart M, Rengifo-Pardo M, Macaya A, Alvar J, Tweed JA. Interventions for American cutaneous and mucocutaneous leishmaniasis. Cochrane Database Syst. Rev. CD004834 (2009).